5 United States Chronic Obstructive Pulmonary Disease( COPD) Drugs Sales( Volume) by Application( 2012-2017) 5.1 United States Chronic Obstructive Pulmonary Disease( COPD) Drugs Sales and Market Share by Application( 2012-2017) 5.2 United States Chronic Obstructive Pulmonary Disease( COPD) Drugs Sales Growth Rate by Application( 2012-2017) 5.3 Market Drivers and Opportunities
6 United States Chronic Obstructive Pulmonary Disease( COPD) Drugs Manufacturers Profiles / Analysis 6.1 GSK 6.1.1 Company Basic Information, Manufacturing Base and Competitors 6.1.2 Chronic Obstructive Pulmonary Disease( COPD) Drugs Product Type, Application and Specification 6.1.2.1 Product A 6.1.2.2 Product B 6.1.3 GSK Chronic Obstructive Pulmonary Disease( COPD) Drugs Sales, Revenue, Price and Gross Margin( 2012-2017) 6.1.4 Main Business / Business Overview 6.2 Novartis 6.2.2 Chronic Obstructive Pulmonary Disease( COPD) Drugs Product Type, Application and Specification 6.2.2.1 Product A 6.2.2.2 Product B 6.2.3 Novartis Chronic Obstructive Pulmonary Disease( COPD) Drugs Sales, Revenue, Price and Gross Margin( 2012-2017) 6.2.4 Main Business / Business Overview 6.3 Boehringer Ingelheim 6.3.2 Chronic Obstructive Pulmonary Disease( COPD) Drugs Product Type, Application and Specification 6.3.2.1 Product A 6.3.2.2 Product B 6.3.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease( COPD) Drugs Sales, Revenue, Price and Gross Margin( 2012-2017) 6.3.4 Main Business / Business Overview 6.4 Sunovion Pharmaceuticals 6.4.2 Chronic Obstructive Pulmonary Disease( COPD) Drugs Product Type, Application and Specification 6.4.2.1 Product A 6.4.2.2 Product B 6.4.3 Sunovion Pharmaceuticals Chronic Obstructive Pulmonary Disease( COPD) Drugs Sales, Revenue, Price and Gross Margin( 2012-2017) 6.4.4 Main Business / Business Overview 6.5 Perforomist 6.5.2 Chronic Obstructive Pulmonary Disease( COPD) Drugs Product Type, Application and Specification 6.5.2.1 Product A 6.5.2.2 Product B 6.5.3 Perforomist Chronic Obstructive Pulmonary Disease( COPD) Drugs Sales, Revenue, Price and Gross Margin( 2012-2017)